MORAGA, Calif., March 29, 2016 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the BIO-Europe Spring 2016 Conference, which will be held in Stockholm, Sweden next week. The presentation will be made by Charles Yeomans, president and chief executive officer of Trigemina, and will occur on Tuesday, April 5, at 5:00 p.m. CET.
"We look forward to presenting at BIO-Europe next week and to having a full schedule of meetings with potential partners and clinical trial collaborators," stated Mr. Yeomans. "We completed a Phase 2 trial for our TI-001 product candidate for migraine headache prophylaxis last year with promising results and are putting the pieces in place for a Phase 2b study that we expect to start later this year."
About BIO-Europe Spring 2016 Conference
BIO-Europe Spring® is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking.
About Trigemina
Trigemina is developing easy-to-use, highly-targeted, nose-to-brain therapies for patients with debilitating CNS disorders. Our platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders with high unmet medical need. Our lead product, a site-specific blocker of CGRP release in the CNS, is in late-stage development for the prevention of high frequency episodic and chronic migraine in both adults and adolescents. www.trigemina.com
Contacts:
Charles Yeomans
President and CEO, Trigemina
925-377-0664
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org
SOURCE Trigemina, Inc.